Group items matching

in title, tags, annotations or url

The following programs have due dates that fall between October 1 - 25, 2013, and these dates are being revised due to the Federal  government shutdown. These revised dates apply whether the proposal is being submitted via the NSF FastLane System or  Grants.gov. Due to compressed proposal deadlines resulting from the shutdown, proposers are advised that they may experience a  delay when contacting IT Help Central with technical support questions. Frequently asked questions regarding these date changes  are available on the Resumption of Operations page on the NSF website at: http://www.nsf.gov/bfa/dias/policy/postshutdown.jsp. 

The purpose of this FOA is to solicit R03 applications for up to two years for secondary analysis of data on aging in the areas of psychology, social epidemiology, economics, sociology, and demography.

The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimers disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.

The National Institutes of Health (NIH) seeks input on the restructuring of the NIH grant application instructions. We invite comments from any interested parties. We encourage feedback from PD/PIs, Administrative Offices, Offices of Sponsored Programs, Systems Administrators, and any other parties that rely on our application submission information.

Chronic Brain Injury is accepting seed grant proposals from cross-college teams of faculty studying topics related to traumatic brain injury, concussion and dementia, including Alzheimer's disease. Five awards of $25,000 are available, and all Ohio State faculty are eligible.

The NIH Research Evaluation and Commercialization Hub (REACH) program is envisioned as a partnership program between NIH and the qualifying research institutions to accelerate the creation of small businesses and the transition of discoveries originating from academic research into products that improve health. REACH Hubs will foster the advancement of therapeutics, preventatives, diagnostics, devices, and tools in a manner consistent with business case development, that address the needs of patients and public health.

The functionality of the NeuroImaging Tools and Resources Collaboratory (NITRC) has enabled three distinct components to flourish: Resources Registry (NITRC-R): a collaboratory enabling the distribution, enhancement, and adoption of neuroimaging tools and resources. Image Repository (NITRC-IR): a curated repository of free neuroimaging datasets meeting global standards. Computational Environment (NITRC-CE): a freely downloadable or pay-as-you-go virtual computing cloud-based platform that is pre-configured with popular neuroimaging tools. NITRC-R has become the major web-based collaborative environment enabling the distribution, enhancement, and adoption of neuroinformatics resources. It currently hosts more than 1,000 tools and resources in areas such as magnetic resonance imaging (MRI), computed tomography (CT), optical imaging, positron emission tomography/single-photon emission computed tomography (PET/SPECT), electroencephalography/magnetoencephalography/electrocorticography (EEG/MEG/ECoG), computational neuroscience, and imaging genomics. Since NITRC's inception, there have been more than 10 million total downloads of tools from NITRC-R.

Recent studies show nearly half of older adults will experience social isolation, which is linked to a broad range of negative physical and psychological outcomes that can be life threatening. Due to geographic isolation, limited access to reliable transportation, and reduced family/social networks as young people move to urban areas for employment, the problem disproportionally impacts older adults in rural areas. By providing older adults with stimulating, meaningful, and enjoyable activities, technology can enhance their sense of connection to family, friends and community, add to their overall quality of life, and help them live independently in their communities of choice. However, technology on its own cannot eliminate social isolation completely and must be combined with increased community engagement, human connectivity, and opportunities for rural residents of all ages to work together to promote healthy aging.

This Funding Opportunity Announcement (FOA) invites applications seeking to examine the outcomes of care for persons with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by identifying home- and community-based services (HCBS) used, as well as barriers to accessing these types of care and unmet needs of persons with AD/ADRD concerning care and services.

The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA ().

The SBIR program, as established by law, is intended to meet the following goals: stimulate technological innovation in the private sector; strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs; increase the commercial application of Federally-supported research results; foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation.

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate tools and resources to facilitate the detailed analysis of brain microconnectivity. Novel and augmented techniques are sought that will ultimately be broadly accessible to the neuroscience community for the interrogation of microconnectivity in healthy and diseased brains of model organisms and humans. Development of technologies that will significantly drive down the cost of connectomics would enable routine mapping of the microconnectivity on the same individuals that have been analyzed physiologically, or to compare normal and pathological tissues in substantial numbers of multiple individuals to assess variability.  Advancements in both electron microscopy (EM) and super resolution light microscopic approaches are sought. Applications that propose to develop approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged. Proof-of-principle demonstrations and/or reference datasets enabling future development are welcome, as are improved approaches for automated segmentation and analysis strategies of neuronal structures in EM images.

The McGovern Institute for Brain Research at the Massachusetts Institute of Technology was established in 2000 by Patrick J. McGovern and Lore Harp McGovern, with the goal of improving human welfare, communication, and understanding through their support for neuroscience research. The institute has announced a call for nominations for its twelfth annual Edward M. Scolnick Prize in Neuroscience. Now in its fifteenth year, the Scolnick Prize is designed to recognize outstanding advances in the field of neuroscience. The prize, which is endowed through a gift from Merck to the McGovern Institute, consists of a $150,000 award, plus an inscribed gift. In addition, the recipient will present a public lecture at the McGovern Institute in spring 2018. A gala dinner for the recipient and invited guests follows the prize lecture. Candidates for the award must be nominated by individuals affiliated with universities, hospitals, medicals schools, or research institutes, with a background in neuroscience. Self-nomination is not permitted.

The purpose of this research is to identify, implement, and evaluate the use of effective strategies and tools for provider and patient use to taper and/or discontinue opioids, benzodiazepines, and other medications in which risk outweighs benefits to prevent falls, overdose, and other injuries among community dwelling older adults.

The goal of this funding opportunity announcement is to continue and expand the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium and enable data-driven discovery and validation of novel targets and biomarkers for AD and AD-related dementias through the development of predictive network models of brain health and disease.

The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) InitiativeSM is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space. It is expected that the application of these new tools and technologies will ultimately lead to new ways to treat, cure, and even prevent brain disorders.

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space. It is expected that the application of these new tools and technologies will ultimately lead to new ways to treat and prevent brain disorders.

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.